Deminger, Anna http://orcid.org/0000-0001-6423-1623
Klingberg, Eva
Geijer, Mats
Göthlin, Jan
Hedberg, Martin
Rehnberg, Eva
Carlsten, Hans
Jacobsson, Lennart T.
Forsblad-d’Elia, Helena
Funding for this research was provided by:
The Health and Medical Care Executive Board of the Västra Götaland
Rune och Ulla Amlövs Stiftelse för Neurologisk och Reumatologisk Forskning
The Swedish Rheumatism Association
Reumatikerdistriktet i Göteborg
Göteborgs Läkaresällskap
Svenska Läkaresällskapet
Västra Götalandsregionen (SE) (agreement concerning research and education of doctors)
Controlling Chronic Inflammatory Diseases with Combined Efforts (COMBINE)
Stiftelsen Reuma Forskningsfond Margareta
Article History
Received: 23 February 2018
Accepted: 10 July 2018
First Online: 3 August 2018
Ethics approval and consent to participate
: The study was approved by the regional ethics committee in Gothenburg, Sweden (reference numbers Dnr 597–08 and Dnr 690–13) and was performed in accordance with the Helsinki declaration. All participants gave their written informed consent.
: Not applicable.
: MG has received consultancy fees from Pfizer and Novartis, outside the submitted work.LTJ has received Advisory Board Fees from Novartis, Celgene and MSD, outside the submitted work.HFd’E has received Advisory Board Fees from Sandoz, Novartis and Abbvie and an unrestricted grant from Novartis, outside the submitted work.AD, EK, JG, MH, ER and HC report no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.